Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.30 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.30 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.30 |
| ▸ | TP53 | P04637 | 1/20 | 0.30 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL335201 | 1.00 | ALDH1A1 (0.38) | ALDH1A1MAPTSMN1; SMN2SLC6A2SLC6A4 | |
| SCHEMBL10703734 | 0.84 | ALDH1A1 (0.40) | ALDH1A1MAPTNPSR1 | |
| SCHEMBL10704022 | 0.84 | ALDH1A1 (0.37) | ALDH1A1MAPT | |
| SCHEMBL10707191 | 0.81 | ALDH1A1 (0.39) | ALDH1A1MAPTSMN1; SMN2SLC6A2SLC6A4 | |
| SCHEMBL6567358 | 0.80 | ALDH1A1 (0.44) | ALDH1A1MAPTNPSR1 | |
| SCHEMBL9816042 | 0.80 | ALDH1A1 (0.34) | ALDH1A1MAPTSLC6A2SLC6A4NPSR1 | |
| SCHEMBL10705306 | 0.79 | TSHR (0.46) | ALDH1A1 | |
| SCHEMBL28098070 | 0.78 | ALOX5 (0.34) | ALDH1A1MAPTNPSR1 | |
| SCHEMBL11160009 | 0.77 | TP53 (0.35) | ALDH1A1TP53CYP3A4 | |
| SCHEMBL88005 | 0.75 | ALDH1A1 (0.54) | ALDH1A1MAPTSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8097708-B2 | 10a-Azalide compound | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2012-01-17 | — | — | US | disclosed |
| US-20090281292-A1 | 10a-Azalide Compound | MEIJI SEIKA PHARMA CO., LTD. (JP) | 2009-11-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090281292-A1 | 10a-Azalide Compound | IL17A, AZI2, HDAC9 | ALDH1A1 1939/4885MAPT 4302/4885SMN1; SMN2 3120/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.